Tensec | $12,000,000 | (Jun 19, 2025)
Grifin | $11,000,000 | (Jun 19, 2025)
Materna Medical | $20,000,000 | (Jun 19, 2025)
Certified by Founder
Lodge
Glycomine Inc.
start up
United States
- San Carlos, California
- 17/04/2025
- Series C
- $115,000,000
Glycomine is developing orphan drugs for serious rare disorders of metabolism and protein misfolding for which no other therapeutic options exist. The company's approach is to use replacement therapies – substrates, enzymes, or proteins – and to target those molecules to clinically relevant cellular compartments. Glycomine’s lead drug candidate, GLM101, is a novel substrate replacement therapy in development to treat phosphomannomutase 2-congenital disorder of glycosylation (PMM2-CDG), a rare disease representing a critical unmet medical need.
- Industry Biotechnology Research
- Website https://www.glycomine.com/
- LinkedIn https://www.linkedin.com/company/glycomine-inc-/
Related People
Steven AxonFounder
United States -
Cohasset, Massachusetts
Specialties: Biotech, Business Development,
Corporate Strategy, Corporate Finance, Alliance Management
NaroIQ | $6,500,000 | (Jun 19, 2025)
Polar | $9,860,072 | (Jun 19, 2025)
Darwix AI | $1,500,000 | (Jun 19, 2025)
Infinity Bio, Inc. | $8,000,000 | (Jun 19, 2025)
HydroBlok | $6,000,000 | (Jun 19, 2025)
Orange Quantum Systems | $13,742,820 | (Jun 19, 2025)
Corvia Medical, Inc. | $55,000,000 | (Jun 18, 2025)
GetZoot | $6,000,000 | (Jun 18, 2025)
AthenaHQ | $2,200,000 | (Jun 18, 2025)